This month, the Journal of the American Medical Association (JAMA) published a collaborative article between the Children’s Hospital of Philadelphia and the University of California concerning the ...

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

The White House’s decision to safeguard $400m in President’s Emergency Plan for AIDS Relief (PEPFAR) funding to support the global human immunodeficiency virus (HIV) emergency provides “hope” to ...

Hengrui Pharma and Kailera Therapeutics have reported positive topline data from the former’s Phase III trial (HRS9531-301) of HRS9531.

SELLAS AML therapy achieved an overall response rate of 33%, exceeding the 20% threshold, with some patient groups achieving 50% ...

SPRIM PRO and ObvioHealth have announced an expansion of their partnership to provide a fully integrated trial solution.

The timing of the exposure during pregnancy made a big difference in the level of risk associated with developing an allergic condition.

Neurocrine Biosciences has presented new one-year data from its Phase III CAHtalyst Adult study of Crenessity for classic CAH.

ViiV's Cabenuva is administered every two months and was offered to HIV patients who achieved viral suppression from daily treatments.

MSD unveiled the launch of the Phase III trials of MK-8527 at the International AIDS Society (IAS) 2025 conference.

Amylyx has presented new exploratory analyses from the Phase II PREVENT and Phase IIb trials of avexitide for PBH treatment.

Takeda’s oral narcolepsy drug, oveporexton, has met the primary and secondary endpoints in two Phase III trials. The FirstLight (NCT06470828) and RadiantLight (NCT06505031) trials both met all their ...